Please login to the form below

Not currently logged in
Email:
Password:

Neon Therapeutics taps Dr Richard Gaynor for R&D leadership role

He recently retired from Lilly after more than 15 years with the firm

Neon Therapeutics Richard GaynorNeon Therapeutics has appointed Dr Richard Gaynor as president of research and development to succeed its interim chief scientific office Robert Tepper, who will continue to sit on the firm's board.

Dr Gaynor recently retired from Lilly's oncology division, where he was spent more than 15 years, most recently as senior vice president of global product development and medical affairs.

At Cambridge, US-based Neon he will be tasked with guiding the immuno-oncology company's research programmes, which are focused on developing neoantigen-based therapeutic vaccines and T cell therapies.

Hugh O'Dowd, chief executive officer of Neon Therapeutics said the company was privileged to have Dr Gaynor join its team.

“Richard brings an enormous depth of oncology experience, having overseen many innovative drugs through early research into clinical development and commercialisation. His knowledge and leadership reinforces Neon Therapeutics' leadership in neoantigen-based immuno-oncology treatments.”

Dr Gaynor began his career in academia before joining Lilly in 2002 to oversee both oncology drug discovery and early clinical development.

12th December 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....